congresses-banner

The content contained is subject

PublicationView

Poster
Quizartinib
COSTEM 2024 | October 24-27, 2024
Other/Multi
QuANTUM-First Trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction and consolidation is associated with improved overall survival in newly diagnosed FLT3-ITD+ AML patients
Alexander E. Perl
Poster
Quizartinib
COSTEM 2024 | October 24-27, 2024
Other/Multi
QuANTUM-First: Safety by treatment phase and by age in newly diagnosed patients with FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia
Richard F. Schlenk

footer